Clinical Scorecard: Case Study: Misinterpretation of Gilbert Syndrome as Drug-Induced Liver Injury Resulting in Ongoing Indirect Hyperbilirubinemia During Tuberculosis Therapy
At a Glance
Category
Detail
Condition
Gilbert Syndrome
Key Mechanisms
Inherited disorder of bilirubin metabolism due to UGT1A1 gene variants leading to impaired bilirubin conjugation.
Target Population
Patients undergoing anti-tuberculosis therapy, particularly in East Asian populations.
Care Setting
Clinical management of tuberculosis
Key Highlights
Isolated indirect hyperbilirubinemia with normal transaminases may indicate Gilbert syndrome rather than DILI.
Misinterpretation of bilirubin levels led to unnecessary treatment interruptions exceeding 1 year.
Genetic testing confirmed Gilbert syndrome, allowing for the resumption of effective tuberculosis therapy.
Guideline-Based Recommendations
Diagnosis
Consider Gilbert syndrome in cases of indirect hyperbilirubinemia with normal liver transaminases during tuberculosis treatment.
Management
Avoid unnecessary cessation of anti-tuberculosis therapy upon identification of Gilbert syndrome.
Monitoring & Follow-up
Monitor bilirubin levels and liver function tests in patients receiving anti-tuberculosis therapy.
Risks
Misdiagnosis can lead to treatment delays and disease progression.
Patient & Prescribing Data
Young adults with pulmonary tuberculosis.
Individualized anti-tuberculosis regimens guided by drug susceptibility testing are essential.
Clinical Best Practices
Perform genetic testing for UGT1A1 variants in patients with unexplained indirect hyperbilirubinemia during tuberculosis treatment.
Educate clinicians on the atypical presentation of Gilbert syndrome to prevent misdiagnosis.
